Atirmociclib not checked
Pfizer · PF-07220060 · Cohort 5
FollowEvery change as it happens, and a Monday email
Trials
8 active
15 in total · 6 in the EU
What this is
- How it works
- Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
- How it’s given
- “Atirmociclib tablet given orally twice daily, plus giredestrant capsule given orally once per day”In the company’s words, NCT07890597 on ClinicalTrials.gov
- Tested for
- Breast Cancer (2 trials), Advanced or Metastatic Breast Cancer (2 trials), Advanced Breast Cancer (2 trials), Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-), Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer and 7 more
- Main trialPhase 3
- “The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior…”In the company’s words, NCT06760637 on ClinicalTrials.gov
- Other names
- PF-07220060 · Cohort 5 · Fed · Cohort 6 · Fasted PPI · Cohort 7 · Fed PPI · Cohort 8 · third tablet formulation
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up6
- 14 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- 2 Jan 2029Phase 3 trial completes · ClinicalTrials.gov
- 27 Aug 2029Phase 2 trial completes · ClinicalTrials.gov
- 7 Oct 2029Phase 2 trial completes · ClinicalTrials.gov
- 22 Mar 2030Phase 1 trial completes · ClinicalTrials.gov
- 13 Apr 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 2 Jan 2029 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | |
| Phase 3Not yet recruiting | 13 Apr 2032 | A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer | |
| Phase 2Active, not recruiting | 12 Jan 2026 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | |
| Phase 2Recruiting | 27 Aug 2029 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors | |
| Phase 2Recruiting | 7 Oct 2029 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | |
| Phase 1/2Active, not recruiting | 5 Sep 2025 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | |
| Phase 1Recruiting | 14 Aug 2027 | A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease | |
| Phase 1Not yet recruiting | 22 Mar 2030 | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors | |
| Phase 2Completed | 10 Jul 2025 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | |
| Phase 1Completed | 12 Apr 2024 | A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults | |
| Phase 1Completed | 23 Jun 2024 | A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults | |
| Phase 1Completed | 11 May 2025 | A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060 | |
| Phase 1Completed | 26 Oct 2025 | A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants | |
| Phase 1Completed | 24 Nov 2025 | A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 | |
| Phase 1Completed | 21 Jul 2026 | Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026